Passive immunotherapy of cancer: perspectives and problems
- 31 July 1991
- journal article
- Published by Elsevier in Journal of Controlled Release
- Vol. 16 (1-2), 101-111
- https://doi.org/10.1016/0168-3659(91)90034-b
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Advantage of Dose Fractionation in Monoclonal Antibody-Targeted RadioimmunotherapyJNCI Journal of the National Cancer Institute, 1990
- Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma.Journal of Clinical Oncology, 1990
- Polyclonal 90yttrium labeled antiferritin for refractory Hodgkin's diseaseInternational Journal of Radiation Oncology*Biology*Physics, 1989
- REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1HThe Lancet, 1988
- Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin ABritish Journal of Cancer, 1988
- Strategies for designing antibody-toxin conjugatesTrends in Biotechnology, 1988
- Treatment of steroid-resistant acute graft-vs-host disease by in vivo administration of an anti-T-cell ricin A chain immunotoxinJAMA, 1988
- The mechanism of action of barley toxin: a type 1 ribosome-inactivating protein with RNA N-glycosidase activityBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1988
- Redesigning Nature's Poisons to Create Anti-Tumor ReagentsScience, 1987
- Continuous cultures of fused cells secreting antibody of predefined specificityNature, 1975